A pharma company that has developed a drug that could be used in patients with epilepsy has launched a crowdfunding campaign to raise funds for development.
Valeant Pharmaceuticals, based in Cambridge, Massachusetts, has launched an Indiegogo campaign that has raised more than $4.7 million from more than 20,000 people in the past two weeks.
It aims to create the first commercial version of its Epidiolex, which is currently being developed by Sanofi-Aventis.
The drug could be on the market in 2018.
Vivek Jain, a professor at the Massachusetts Institute of Technology, told The Sunday Times the drug was a milestone for epilepsy and could help millions of people.
“We believe that this is the most powerful drug ever developed in the field,” he said.
Valeants drug will be tested in clinical trials in the coming monthsDr Jain said there was a huge potential market for epilepsy drugs because the treatment could be made available in the UK for people with the disease.””
I think this will change the landscape of epilepsy treatment, and it will change how we treat epilepsy.”
Valeants drug will be tested in clinical trials in the coming monthsDr Jain said there was a huge potential market for epilepsy drugs because the treatment could be made available in the UK for people with the disease.
“You don’t have to be a doctor to prescribe a drug, it’s just a prescription that’s made by a doctor,” he added.
“It’s an innovative drug, so it’s going to be difficult to get a patient who has epilepsy to take it, but I think it’s an exciting opportunity.”
A similar approach could be taken to treat epilepsy in the developing world, he said, as it could help develop treatments that are cheaper and less toxic.
“In the developing worlds, we have had a lot of success in developing drugs that are able to be made into vaccines, so that’s a really exciting area of medicine, but we have to keep looking at the costs of the drug, the toxicity, the side effects and the potential side effects,” he told The Times.
“So that’s the challenge, is to do that right, and that’s what this is all about.”
“We’re looking at how do we deliver it to people who need it, and how do they make the drug available in a way that makes sense for them, and also makes it affordable for them.”
Epidemiologist Dr David Gonsalves, a senior lecturer in epilepsy at the University of Oxford, said the company was taking the best parts of its existing drugs, adding that he was impressed with the potential of the technology.
“I think the Epidietix is a fantastic approach to epilepsy treatment,” he wrote on Facebook.
“Epidiolyses is a disease that’s complex and has so many different causes.
Epidiol is one of the most promising new epilepsy treatments available and this could be a huge breakthrough for epilepsy.”
The Epidemioslex drug will target two types of epilepsy – those that affect the parts of the brain responsible for motor control and those that have no effect at all.
In clinical trials, the drug is currently approved for use in people with a history of severe epilepsy or in people who have had two previous seizures.
The drug is also available for people to take in combination with other treatments to reduce seizures.”
Our work in this area is continuing and we expect to finalise the development of the next-generation Epidiotoxide drug, and we are hopeful to deliver this product in the early 2020s.”
The drug is also available for people to take in combination with other treatments to reduce seizures.
The company is also working on a new epilepsy treatment that could provide relief from pain and other symptoms, including depression.